Note One). Nothing you might stumble across here represents, in any form or fashion, a stock recommendation. Why? Well simply cause it ain’t. Besides..what sort of moron would act on a stock recommendation from someone called Big Dumb Hick? Only an imbecile - right? Always perform your own due diligence.
Tempus AI - Market Alias = TEM
Tempus AI, Inc. operates as a healthcare technology company. It engages in providing next generation sequencing diagnostics, polymerase chain reaction profiling, molecular genotyping, and other anatomic and molecular pathology testing to healthcare providers, pharmaceutical companies, biotechnology companies, researchers, and other third parties.
A Few Data Points:
Current Price: $65.87
52 Week Range: 22.89 - 91.45
30 Day Momentum: +22.5%
YTD: + 95.11%
Market Cap: $10.8B (give or take)
Short Interest: 11.3%
Revenue Last 4 QTRS:
FQ1: 255.74M
FQ4: 200.68M
FQ3: 180.93M
FQ2: 165.97M
FQ1 Press Release :
CC Transcript:
Highlights:
- EPS Beat by .03 Cents
- Revenue Beat by $7.61M
- Revenue Growth of 75.4% YoY
- Quarterly gross profit increased 99.8% year-over-year, reaching $155.2 million with continued gross margin improvement in both Genomics and Data and services
- Announced multi-year, strategic collaborations with AstraZeneca and Pathos to work together to build the largest multimodal foundation model in oncology, resulting in additional $200.0 million in data licensing and model development fees over the next 3 years.
- Increasing full year 2025 revenue guidance to $1.25 billion, representing approximately 80% growth year-over-year. Expect positive Adjusted EBITDA of $5 million for full year 2025, increasing approximately $110 million over 2024.
CC Quote from CEO:
“The business is performing well with revenues growing, margins improving, and our costs remaining in check, allowing us to demonstrate significant year-over-year operating leverage,” said Eric Lefkofsky, Founder and CEO of Tempus. “Our strategic investments in AI have us uniquely positioned to advance what is possible in diagnostics and drug development, as evidenced by our announcement to build the largest foundation model in oncology with AstraZeneca and Pathos. We believe this is just the beginning as more and more healthcare providers and life science companies embrace AI.”
A couple of Scouting Reports:
https://seekingalpha.com/article/4789726-tempus-ai-firing-on-all-cylinders#source=section_asset%3Arelated-analysis%7Csection%3Aright_rail%7Cfirst_level_url%3Aarticle%7Cline%3A1%7Cpos%3Aundefined
All The Best,
Big Dumb Hick - Considering